Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.

[1]  E. Leifer,et al.  Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. , 2015, The Lancet. Haematology.

[2]  A. Kulasekararaj,et al.  Sweet spot for cyclophosphamide: a balancing act. , 2015, The Lancet. Haematology.

[3]  K. Kawa,et al.  Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia , 2015, Bone Marrow Transplantation.

[4]  N. Ali,et al.  Reduced-intensity conditioning hematopoietic stem cell transplantation: looking forward to an international consensus , 2015, Blood research.

[5]  H. Sengeløv,et al.  Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis , 2015, Haematologica.

[6]  Ji Won Lee,et al.  Pharmacokinetics of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation , 2014 .

[7]  B. Dumitriu,et al.  Bone marrow failure and the telomeropathies. , 2014, Blood.

[8]  H. Nakasone,et al.  A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia , 2014, International Journal of Hematology.

[9]  K. Sanpakit,et al.  Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva‐Asia Blood and Marrow Transplantation Group , 2013, British journal of haematology.

[10]  M. Aljurf,et al.  Standard treatment of acquired SAA in adult patients 18–40 years old with an HLA-identical sibling donor , 2013, Bone Marrow Transplantation.

[11]  E. Leifer,et al.  Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  P. Veys,et al.  Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience , 2012, British journal of haematology.

[13]  J. Fay,et al.  Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. , 2011, Blood.

[14]  E. Shpall,et al.  Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia , 2011, Leukemia & lymphoma.

[15]  Sang Kyu Park,et al.  Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  E. Lanino,et al.  Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party , 2010, Haematologica.

[17]  P. Bartolomeo,et al.  Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants , 2010, Bone Marrow Transplantation.

[18]  J. Cavenagh,et al.  Guidelines for the diagnosis and management of aplastic anaemia , 2009, British journal of haematology.

[19]  M. Schnitzler,et al.  A Prospective, Randomized, Double-Blinded Comparison of Thymoglobulin Versus Atgam for Induction Immunosuppressive Therapy: 10-Year Results , 2008, Transplantation.

[20]  J. Klein,et al.  Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia , 2008, British journal of haematology.

[21]  R. Collins,et al.  Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. , 2006, Blood.

[22]  F. Frassoni,et al.  Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG) , 2001, Bone Marrow Transplantation.

[23]  L. Robison,et al.  Late outcomes after bone marrow transplant for aplastic anaemia. , 2000 .

[24]  J. Fay,et al.  Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. , 2000, Blood.

[25]  H. Deeg,et al.  Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. , 1997, Blood.

[26]  H. Deeg,et al.  Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. , 1994, Blood.

[27]  J. Pierga,et al.  Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.